TY - JOUR
T1 - Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis
AU - Salek, Sherveen S.
AU - Leder, Henry A.
AU - Butler, Nicholas J.
AU - Gan, Theresa J.
AU - Dunn, James P.
AU - Thorne, Jennifer E.
N1 - Funding Information:
Dr. Thorne is the recipient of a RPB Sybil B. Harrington Special Scholars Award. Dr. Leder is supported by unrestricted funds from Research to Prevent Blindness. Dr. Thorne serves on a scientific advisory board for Allergan, Inc.
PY - 2013/8
Y1 - 2013/8
N2 - Purpose: To describe the effectiveness of periocular corticosteroid injections for the control of intraocular inflammation associated with noninfectious uveitis. Methods: A total of 81 patients (109 eyes) who received a periocular injection were evaluated for active inflammation, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications, including macular edema. Results: Of all eyes, 36% (95%CI: 25%, 45%) demonstrated clinical resolution of inflammation at the 1-month visit after first injection, and 48% (95%CI: 37%, 59%) at 3 months. For multiple injections, 50% (95%CI: 28%, 72%) demonstrated resolution of inflammation at 1 month after the last injection, and 41% (95%CI: 20%, 63%) resolution of inflammation at 3 months after the last injection. Of the 49 eyes that initially responded, the estimated median time to recurrence was 7.6 months. Conclusions: Approximately half of the treated eyes had resolution of intraocular inflammation at 3 months after corticosteroid injection.
AB - Purpose: To describe the effectiveness of periocular corticosteroid injections for the control of intraocular inflammation associated with noninfectious uveitis. Methods: A total of 81 patients (109 eyes) who received a periocular injection were evaluated for active inflammation, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications, including macular edema. Results: Of all eyes, 36% (95%CI: 25%, 45%) demonstrated clinical resolution of inflammation at the 1-month visit after first injection, and 48% (95%CI: 37%, 59%) at 3 months. For multiple injections, 50% (95%CI: 28%, 72%) demonstrated resolution of inflammation at 1 month after the last injection, and 41% (95%CI: 20%, 63%) resolution of inflammation at 3 months after the last injection. Of the 49 eyes that initially responded, the estimated median time to recurrence was 7.6 months. Conclusions: Approximately half of the treated eyes had resolution of intraocular inflammation at 3 months after corticosteroid injection.
KW - Control of inflammation
KW - Effectiveness
KW - Periocular corticosteroids
KW - Side effects
KW - Uveitis
UR - http://www.scopus.com/inward/record.url?scp=84879769039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879769039&partnerID=8YFLogxK
U2 - 10.3109/09273948.2013.767353
DO - 10.3109/09273948.2013.767353
M3 - Article
C2 - 23617776
AN - SCOPUS:84879769039
SN - 0927-3948
VL - 21
SP - 257
EP - 263
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 4
ER -